Zacks Investment Research upgraded shares of NEWLINK GENETIC (NLNK) from NEUTRAL to OUTPERFORM on October 22, 2014, with a target price of $36.20.
NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NEWLINK GENETIC (NLNK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment